Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9822185
SERIAL NO

14879331

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
STALLERGENES92160 ANTONY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Batard, Thierry Versailles, FR 8 8
Mascarell, Laurent Paris, FR 6 2
Moingeon, Philippe Verrieres le Buisson, FR 24 73
Nony, Emmanuel Antony, FR 36 246
Zimmer, Aline Massy, FR 7 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 21, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 21, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00